Heart in Patients Infected with 2019 Novel Coronavirus (COVID-19)

2020 ◽  
Author(s):  
Abdallah Fayssoil ◽  
Benjamin Davido ◽  
Hazrije Mustafic ◽  
Aurélien Dinh ◽  
Nicolas Mansencal
Keyword(s):  
Infectious Disease ◽  
Severe Acute Respiratory Syndrome ◽  
Cardiac Function ◽  
Prognostic Value ◽  
Emerging Infectious Disease ◽  
Renin Angiotensin ◽  
Novel Coronavirus

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging infectious disease with currently a pandemic state. Cardiac function can be involved, affecting prognosis, in addition with lung feature severity, particularly in patients with comorbidities. Since the renin angiotensin aldosterone (RAA) system may interact with SARS-Cov-2, researches are still ongoing to assess the prognostic value of RAA blockers in cardiology.

scholarly journals COVID-19 R0: Magic number or conundrum?

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Giulio Viceconte ◽  
Nicola Petrosillo
Keyword(s):  
Infectious Disease ◽  
Magic Number ◽  
Emerging Infectious Disease ◽  
Chinese City ◽  
Sporadic Cases ◽  
Novel Coronavirus

There is an increasing concern about COVID-19 worldwide. This is a new emerging infectious disease caused by a novel coronavirus (SARS-CoV-2), which recently broke out from the Chinese city of Wuhan and has quickly spread in China, with sporadic cases in each continent [...].

scholarly journals 2019-nCoV: The Identify-Isolate-Inform (3I) Tool Applied to a Novel Emerging Coronavirus

2020 ◽  
Vol 21 (2) ◽  
pp. 184-190 ◽  
Author(s):  
Kristi Koenig ◽  
Christian Bey ◽  
Eric McDonald
Keyword(s):  
Infectious Disease ◽  
Ebola Virus ◽  
High Volume ◽  
The United States ◽  
Emerging Infectious Disease ◽  
International Travel ◽  
Initial Assessment ◽  
Public Health Agencies ◽  
Epidemiological Risk ◽  
Novel Coronavirus

2019 Novel Coronavirus (2019-nCoV) is an emerging infectious disease closely related to MERS-CoV and SARS-CoV that was first reported in Wuhan City, Hubei Province, China in December 2019. As of January 2020, cases of 2019-nCoV are continuing to be reported in other Eastern Asian countries as well as in the United States, Europe, Australia, and numerous other countries. An unusually high volume of domestic and international travel corresponding to the beginning of the 2020 Chinese New Year complicated initial identification and containment of infected persons. Due to the rapidly rising number of cases and reported deaths, all countries should be considered at risk of imported 2019-nCoV. Therefore, it is essential for prehospital, clinic, and emergency department personnel to be able to rapidly assess 2019-nCoV risk and take immediate actions if indicated. The Identify-Isolate-Inform (3I) Tool, originally conceived for the initial detection and management of Ebola virus and later adjusted for other infectious agents, can be adapted for any emerging infectious disease. This paper reports a modification of the 3I Tool for use in the initial detection and management of patients under investigation for 2019-nCoV. After initial assessment for symptoms and epidemiological risk factors, including travel to affected areas and exposure to confirmed 2019-nCoV patients within 14 days, patients are classified in a risk-stratified system. Upon confirmation of a suspected 2019-nCoV case, affected persons must immediately be placed in airborne infection isolation and the appropriate public health agencies notified. This modified 3I Tool will assist emergency and primary care clinicians, as well as out-of-hospital providers, in effectively managing persons with suspected or confirmed 2019-nCoV.

scholarly journals Moving Average Based Index for Judging the Peak of the COVID-19 Epidemic

2020 ◽  
Vol 17 (15) ◽  
pp. 5288 ◽  
Author(s):  
Yunting He ◽  
Xiaojin Wang ◽  
Hao He ◽  
Jing Zhai ◽  
Bingshun Wang
Keyword(s):  
Infectious Disease ◽  
Hong Kong ◽  
Moving Average ◽  
Hubei Province ◽  
Emerging Infectious Disease ◽  
Evaluation Index ◽  
Normal Life ◽  
The World ◽  
Novel Coronavirus ◽  
Reported Data

A pneumonia outbreak caused by a novel coronavirus (COVID-19) has spread around the world. A total of 2,314,621 laboratory-confirmed cases, including 157,847 deaths (6.8%) were reported globally by 20 April 2020. Common symptoms of COVID-19 pneumonia include fever, fatigue, and dry cough. Faced with such a sudden outbreak of emerging infectious disease, traditional models for predicting the peak of the epidemic often show inconsistent results. With the aim to timely judge the epidemic peak and provide support for decisions for resuming production and returning to normal life based on publicly reported data, we used a seven-day moving average of log-transformed daily new cases (LMA) to establish a new index named the “epidemic evaluation index” (EEI). We used SARS epidemic data from Hong Kong to verify the practicability of the new index, and then applied it to the COVID-19 epidemic analysis. The results showed that the epidemic peaked, respectively, on 9 February and 5 February 2020, in Hubei Province and other provinces in China. The proposed index can be applied for judging the epidemic peak. While the global COVID-19 epidemic reached its peak in the middle of April, the epidemic peaks in some countries have not yet appeared. Global and united efforts are still needed to eventually eliminate the epidemic.

scholarly journals Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century

2020 ◽  
Vol 22 (6) ◽  
pp. 432-450 ◽  
Author(s):  
Ahmad Tavakoli ◽  
Katayon Vahdat ◽  
Mohsen Keshavarz ◽  
◽  
◽  
...  
Keyword(s):  
Infectious Disease ◽  
21St Century ◽  
Emerging Infectious Disease ◽  
Novel Coronavirus

scholarly journals Containment, Contact Tracing and Asymptomatic Transmission of Novel Coronavirus Disease (COVID-19): A Modelling Study

2020 ◽  
Vol 9 (10) ◽  
pp. 3125 ◽  
Author(s):  
Ryo Kinoshita ◽  
Asami Anzai ◽  
Sung-mok Jung ◽  
Natalie M. Linton ◽  
Takeshi Miyama ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
Symptom Onset ◽  
Process Model ◽  
Branching Process ◽  
Contact Tracing ◽  
The Novel ◽  
Global Pandemic ◽  
Novel Coronavirus

When a novel infectious disease emerges, enhanced contact tracing and isolation are implemented to prevent a major epidemic, and indeed, they have been successful for the control of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which have been greatly reduced without causing a global pandemic. Considering that asymptomatic and pre-symptomatic infections are substantial for the novel coronavirus disease (COVID-19), the feasibility of preventing the major epidemic has been questioned. Using a two-type branching process model, the present study assesses the feasibility of containing COVID-19 by computing the probability of a major epidemic. We show that if there is a substantial number of asymptomatic transmissions, cutting chains of transmission by means of contact tracing and case isolation would be very challenging without additional interventions, and in particular, untraced cases contribute to lowering the feasibility of containment. Even if isolation of symptomatic cases is conducted swiftly after symptom onset, only secondary transmissions after the symptom onset can be prevented.

scholarly journals Clinical characteristics of COVID-19 and personal protective equipment for trauma surgeons

2020 ◽  
pp. 81-83
Keyword(s):  
Infectious Disease ◽  
Phylogenetic Analysis ◽  
Severe Acute Respiratory Syndrome ◽  
Clinical Characteristics ◽  
Rna Viruses ◽  
Protective Equipment ◽  
Whole Genome ◽  
Positive Sense ◽  
Novel Coronavirus ◽  
Trauma Surgeons

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus from the coronavirus family (1) regarded as enveloped, positive-sense, single-stranded ribonucleic acid (RNA) viruses with helical symmetric nucleocapsid (2). According to the whole genome sequencing and phylogenetic analysis of coronavirus strains, a distinct clade of betacoronavirus is shown to be associated with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (3). This novel clade is called the 2019 novel coronavirus (2019-nCoV) and due to more similarity to the SARS virus is also called severe acute respiratory syndrome coronavirus 2. The disease is known as COVID-19.

scholarly journals Advances in treatment of COVID-19

2020 ◽  
Vol 1 ◽  
pp. 1
Author(s):  
Qi Wu ◽  
Yong Xu ◽  
Wen-Pan Peng ◽  
Fan-Chao Feng ◽  
Zhi-Chao Wang ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Severe Acute Respiratory Syndrome ◽  
Disease Control ◽  
Human Health ◽  
The Novel ◽  
Recent Advances ◽  
Global Pandemic ◽  
Acute Infectious Disease ◽  
Novel Coronavirus

The novel coronavirus pneumonia is an acute infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The global pandemic of this novel coronavirus pneumonia has greatly threatened human health and brought enormous economy losses. By the end of May 20, 2020, the pandemic of this disease had caused more than 2.70 million infections and more than 320 thousand deaths. This paper reviewed the recent advances in the treatment of the novel coronavirus pneumonia to provide basic references for disease control.

Sign in / Sign up

Export Citation Format

Share Document